Sökning: WFRF:(Arriagada Rodrigo)
> (2010-2014) >
Long-term results o...
-
Arriagada, RodrigoKarolinska Institutet
(författare)
Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer.
- Artikel/kapitelEngelska2010
Förlag, utgivningsår, omfång ...
Nummerbeteckningar
-
LIBRIS-ID:oai:gup.ub.gu.se/112878
-
https://gup.ub.gu.se/publication/112878URI
-
https://doi.org/10.1200/JCO.2009.23.2272DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:119792242URI
Kompletterande språkuppgifter
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
PURPOSE Based on 5-year or shorter-term follow-up data in recent randomized trials, adjuvant cisplatin-based chemotherapy is now generally recommended after complete surgical resection for patients with non-small-cell lung cancer (NSCLC). We evaluated the results of the International Adjuvant Lung Cancer Trial study with three additional years of follow-up. PATIENTS AND METHODS Patients with completely resected NSCLC were randomly assigned to three or four cycles of cisplatin-based chemotherapy or to observation. Cox models were used to evaluate treatment effect according to follow-up duration. Results The trial included 1,867 patients with a median follow-up of 7.5 years. Results showed a beneficial effect of adjuvant chemotherapy on overall survival (hazard ratio [HR], 0.91; 95% CI, 0.81 to 1.02; P = .10) and on disease-free survival (HR, 0.88; 95% CI, 0.78 to 0.98; P = .02). However, there was a significant difference between the results of overall survival before and after 5 years of follow-up (HR, 0.86; 95% CI, 0.76 to 0.97; P = .01 v HR, 1.45; 95% CI, 1.02 to 2.07; P = .04) with P = .006 for interaction. Similar results were observed for disease-free survival. The analysis of non-lung cancer deaths for the whole period showed an HR of 1.34 (95% CI, 0.99 to 1.81; P = .06). CONCLUSION These results confirm the significant efficacy of adjuvant chemotherapy at 5 years. The difference in results beyond 5 years of follow-up underscores the need for the long-term follow-up of other adjuvant lung cancer trials and for a better identification of patients deriving long-term benefit from adjuvant chemotherapy.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Dunant, Ariane
(författare)
-
Pignon, Jean-Pierre
(författare)
-
Bergman, Bengt,1953Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin,Institute of Medicine, Department of Internal Medicine(Swepub:gu)xbeben
(författare)
-
Chabowski, Mariusz
(författare)
-
Grunenwald, Dominique
(författare)
-
Kozlowski, Miroslaw
(författare)
-
Le Péchoux, Cécile
(författare)
-
Pirker, Robert
(författare)
-
Pinel, Maria-Izabel Sathler
(författare)
-
Tarayre, Michèle
(författare)
-
Le Chevalier, Thierry
(författare)
-
Karolinska InstitutetInstitutionen för medicin, avdelningen för invärtesmedicin
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Journal of clinical oncology28:1, s. 35-421527-7755
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Arriagada, Rodri ...
-
Dunant, Ariane
-
Pignon, Jean-Pie ...
-
Bergman, Bengt, ...
-
Chabowski, Mariu ...
-
Grunenwald, Domi ...
-
visa fler...
-
Kozlowski, Miros ...
-
Le Péchoux, Céci ...
-
Pirker, Robert
-
Pinel, Maria-Iza ...
-
Tarayre, Michèle
-
Le Chevalier, Th ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
- Artiklar i publikationen
-
Journal of clini ...
- Av lärosätet
-
Göteborgs universitet
-
Karolinska Institutet